Afinitor Wins FDA Nod For Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The mTor inhibitor targets Sutent or Nexavar treatment failures.
You may also be interested in...
Lilly Prepares for Sales Pressures in 2011 to 2014
Facing a patent cliff, the Indianapolis company affirms faith in its pipeline, emerging markets strategy, and bolt-on deals.
Lilly Prepares for Sales Pressures in 2011 to 2014
Facing a patent cliff, the Indianapolis company affirms faith in its pipeline, emerging markets strategy, and bolt-on deals.
Supplemental Approval For Benign Tumors May Double Afinitor's Market
Novartis' Afinitor (everolimus) has approximately doubled its market size with FDA approval for a type of benign tumor that occurs in children with a genetic defect and was previously treatable only by surgery.